Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2020-07-24 Earnings Release
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB bimekizumab BE Radiant ENG
Earnings Release Classification · 99% confidence The document is a press release dated July 24th, 2020, announcing positive results from the Phase 3b BE RADIANT study comparing bimekizumab to Cosentyx for plaque psoriasis. It contains key financial/operational highlights, quotes from management, details about the clinical trial, and forward-looking statements. This format is characteristic of an initial announcement of periodical financial/operational results, which aligns with the definition of an Earnings Release (ER). It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a formal Investor Presentation (IP), but rather the initial public announcement of study outcomes relevant to investors and the market. Q3 2020
2020-07-24 English
UCB bimekizumab BE Radiant FR
Regulatory Filings Classification · 95% confidence The document is a press release dated July 24, 2020, from UCB, announcing positive results from the Phase 3b BE RADIANT study comparing bimekizumab against Cosentyx for psoriasis treatment. It details clinical endpoints (PASI 100), quotes executives and researchers, and includes standard sections like 'About BE RADIANT', 'About bimekizumab', and 'Forward-Looking Statements'. This format—a formal announcement of clinical trial results intended for investors and the public—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it focuses on announcing new clinical data and its implications, it aligns best with the 'Earnings Release' category, which often encompasses major operational or clinical milestones, even if not strictly quarterly financial results. It is not a full Annual Report (10-K), a transcript (CT), or a formal regulatory filing like a DEF 14A or 8-K (though it mentions 'Informations réglementées'). Given the content is a major announcement of positive study data, ER is the most appropriate fit among the options provided for a significant corporate update.
2020-07-24 French
UCB bimekizumab BE Radiant NL
Regulatory Filings Classification · 99% confidence The document is dated 'Brussel, België – 24 juli 2020 – Gereguleerde informatie - Interne informatie' and announces positive Phase 3 trial results for the drug Bimekizumab compared to Cosentyx® for psoriasis. It details clinical endpoints (PASI 100, PASI 75), includes quotes from management and researchers, and concludes with standard boilerplate sections about the drug, the disease, and forward-looking statements. This structure is characteristic of an initial announcement of periodic financial or clinical results, focusing on key highlights rather than a comprehensive report (like a 10-K or IR). Therefore, it fits the definition of an Earnings Release (ER), even though the 'earnings' here are clinical trial results, which often share the same release format as financial earnings. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a Management Discussion & Analysis (MDA). It is a press release announcing significant data, aligning best with the 'Earnings Release' (ER) category for initial result announcements.
2020-07-24 Dutch
200723 - Transparency notification press release FMR LLC .pdf
Major Shareholding Notification Classification · 99% confidence The document is a 'Transparency notification' from FMR LLC to UCB SA/NV, detailing that FMR LLC's holding in UCB shares crossed the 3% threshold on July 15, 2020. This type of filing, which reports changes in significant share ownership (insider/major shareholder transactions), directly corresponds to the definition of Major Shareholding Notification (MRQ). The text explicitly mentions 'Threshold crossed: 3%' and details the holdings of various affiliates, which is the core function of an MRQ filing under relevant disclosure laws (Article 14 mentioned).
2020-07-23 English
200723 - Notification de transparence comm. de presse FMR LLC .pdf
Director's Dealing Classification · 98% confidence The document is a 'Déclaration de transparence' (Transparency Declaration) from FMR LLC regarding a change in its shareholding in UCB SA, specifically crossing the 3% threshold on July 15, 2020. This type of filing, which reports personal share transactions by executives or significant changes in major share ownership, directly corresponds to the definition of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the document explicitly details the crossing of a significant ownership threshold (3%) and lists the exact number of shares held by the entity and its related parties, it is a notification of a change in significant share ownership. Comparing the options: - DIRS (Director's Dealing): Usually refers to trades by directors/executives. While related, this is a notification by a large institutional shareholder (FMR LLC). - MRQ (Major Shareholding Notification): This category fits perfectly as it covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. Therefore, the most accurate classification is MRQ.
2020-07-23 French
200723 - Transparantieverklaring persbericht FMR LLC .pdf
Director's Dealing Classification · 98% confidence The document is a formal notification ('Kennisgeving') issued by UCB NV regarding a change in significant shareholding by FMR LLC. It explicitly mentions crossing a threshold (3%) based on the law of May 2, 2007, concerning the disclosure of major shareholdings ('openbaarmaking van belangrijke deelnemingen'). This content directly corresponds to notifications about changes in significant share ownership levels, which maps to the Major Shareholding Notification category (MRQ). The document details the exact number of shares and the resulting percentage held by the entity and its affiliates.
2020-07-23 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.